Publications by authors named "Lars Hemkens"

Claim this Profile
M
Machine-learning assisted screening for evidence synthesis: Methodological case study of the ASReview tool.
Kim Boesen, Pascal Dueblin, Lars G Hemkens, Perrine Janiaud, Julian Hirt

J Clin Transl Sci· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Serum Neurofilament Light Chain in Multiple Sclerosis: Superiority of Age- and BMI-Corrected Z Scores/Percentiles Over Absolute Cutoff Values for Prediction of Treatment Response.
Maximilian Einsiedler, Aleksandra Maleska Maceski, Sofia Sandgren, Johanna Oechtering, Sabine Schaedelin, Lars G Hemkens

Ann Clin Transl Neurol· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Retrospective use of the Pragmatic-Explanatory Continuum Indicator Summary-2 trial design tool to assess design choices in randomized controlled trials: an empirical review.
Andrew Willis, Frances Shiely, Alison H Howie, Shaun Treweek, Monica Taljaard, Lars Hemkens

J Clin Epidemiol· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pragmatic evidence and the nature of randomized trials.
Perrine Janiaud, Lars G Hemkens

J Clin Epidemiol· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Levodopa Added to Stroke Rehabilitation: The ESTREL Randomized Clinical Trial.
Stefan T Engelter, Josefin E Kaufmann, Annaelle Zietz, Andreas R Luft, Alexandros Polymeris, Lars G Hemkens

JAMA· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Colchicine for the secondary prevention of cardiovascular events.
Fahim Ebrahimi, Ramin Ebrahimi, Maximilian Beer, Christof Manuel Schönenberger, Hannah Ewald, Lars G Hemkens

Cochrane Database Syst Rev· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
GFAP and NfL as predictors of disease progression and relapse activity in fingolimod-treated multiple sclerosis.
Aleksandra Maleska Maceski, Pascal Benkert, Maximilian Einsiedler, Sabine Schaedelin, Johanna Oechtering, Lars G Hemkens

Brain· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Agreement of treatment effects in decentralised trials versus traditional trials: meta-epidemiological study.
Louise Chaboud, Perrine Janiaud, Julian Hirt, Lars G Hemkens

BMJ· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Mixed-methods process evaluation of ctDNA use to guide decision-making in patients with advanced solid cancers: study protocol for a substudy of the LIQPLAT trial.
Johannes M Schwenke, Andreas M Schmitt, Stuart McLennan, Perrine Janiaud, Heinz Läubli, Lars G Hemkens

BMJ Open· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Single-dose Versus 3-day Antimicrobial Prophylaxis in Transurethral Resection or Photoselective Vaporization of the Prostate: A Multicenter, Randomized, Placebo Controlled Trial (CITrUS Trial).
Kathrin Bausch, Benjamin Speich, Deborah R Vogt, Lars G Hemkens, Maeve Dreher

Eur Urol Focus· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Single-Arm Trials Can Provide Randomized Real-World Evidence: The Random Invitation Single-Arm Trial Design.
Perrine Janiaud, John P A Ioannidis, Benjamin Kasenda, Atle Fretheim, Steven N Goodman, Lars G Hemkens

Ann Intern Med· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Personalized treatment decision algorithms for the clinical application of serum neurofilament light chain in multiple sclerosis: A modified Delphi Study.
Özgür Yaldizli, Pascal Benkert, Lutz Achtnichts, Amit Bar-Or, Viviane Bohner-Lang, Lars G Hemkens

Mult Scler· July 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Reply to: On meta-analytic models and the effect of hydroxychloroquine use in COVID-19.
Andreas M Schmitt, Cathrine Axfors, David Moher, Steven N Goodman, John P A Ioannidis, Lars G Hemkens

Nat Commun· July 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Relative risks of adverse effects across different opioid agonist treatments-A systematic review and meta-analysis.
Maximilian Meyer, Eriks Strazdins, Adrian Guessoum, Jean N Westenberg, Christian Appenzeller-Herzog, Lars G Hemkens

Addiction· June 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
Gaps in the Ottawa Statement on the Ethical Design and Conduct of Cluster Randomized Trials: a citation analysis reveals a need for updated ethics guidelines.
Cory E Goldstein, Jessica du Toit, Nicholas B Murphy, Stuart G Nicholls, Julia F Shaw, Lars G Hemkens

Res Integr Peer Rev· June 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Results reporting for clinical trials led by medical universities and university hospitals in the nordic countries was often missing or delayed.
Gustav Nilsonne, Susanne Wieschowski, Nicholas J DeVito, Maia Salholz-Hillel, Love Ahnström, Lars G Hemkens

J Clin Epidemiol· May 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Master protocol for a series of cohort-based randomized controlled trials to test tools to communicate research results to study participants and others with relevant lived experience: the SPIN-CLEAR Trials.
Brett D Thombs, Claire Adams, Elsa-Lynn Nassar, Marie-Eve Carrier, Meira Golberg, Lars G Hemkens

Trials· May 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Core GRADE 4: rating certainty of evidence-risk of bias, publication bias, and reasons for rating up certainty.
Gordon Guyatt, Ying Wang, Prashanti Eachempati, Alfonso Iorio, M Hassan Murad, Lars G Hemkens

BMJ· May 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Core GRADE 5: rating certainty of evidence-assessing indirectness.
Gordon Guyatt, Alfonso Iorio, Hans De Beer, Andrew Owen, Thomas Agoritsas, Lars G Hemkens

BMJ· May 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Meta-analysis of individual participant data and informed consent: a small step, but important and neglected.
Rafael Dal-Ré, Lars G Hemkens

J Clin Epidemiol· April 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Association of cancer incidence and randomized trial evidence for FDA approval of new cancer drugs.
Andreas M Schmitt, Amanda Herbrand, Benjamin Kasenda, Lars G Hemkens

Am J Epidemiol· March 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Communicating scientific evidence: drugs for Alzheimer's disease as a case study.
Kasper P Kepp, Poul F Høilund-Carlsen, Ioana A Cristea, Robert G Cumming, Timothy Daly, Lars G Hemkens

Curr Med Res Opin· February 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Microsurgical versus complex physical decongestive therapy for chronic breast cancer-related lymphoedema.
Yvonne Haas, Olivia P Williams, Jaume Masia, Gemma Pons, Erin M Taylor, Lars G Hemkens

Cochrane Database Syst Rev· February 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The LYMPH trial: comparing microsurgical with conservative treatment for chronic breast cancer-associated lymphoedema - study protocol of a pragmatic randomised international multicentre superiority trial.
Elisabeth A Kappos, Yvonne Haas, Alexandra Schulz, Florian Peters, Shakuntala Savanthrapadian, Lars Hemkens

BMJ Open· February 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Treatment persistence and clinical outcomes in patients starting B cell depleting therapies within the Swiss MS Cohort.
Giulio Disanto, Sabine Schaedelin, Johanna Oechtering, Johannes Lorscheider, Riccardo Galbusera, Lars G Hemkens

Mult Scler J Exp Transl Clin· February 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis